# Fourth International Chordoma Research Workshop

## Agenda

#### Wednesday, March 20

6:00pm – 8:00pm	Registration
	Location: 3 <sup>rd</sup> Floor Rotunda
7:00pm - 9:00pm	Welcome Reception
•	Location: Catwalk Bar on 3 <sup>rd</sup> Floor Rotunda

#### Thursday, March 21

Thursday, March 21		
7:00am – 4:30pm	Registration	
	Location: Liberty Ballroom Foyer – 2 <sup>nd</sup> Floor	
7:00am – 8:00am	Continental Breakfast Location: Liberty Ballroom Foyer – 2 <sup>nd</sup> Floor	
8:00am – 8:10am	Opening Session: Welcome and introductions	
0.00diii 0.10diii	Location: Liberty Ballroom – 2 <sup>nd</sup> Floor	
8:10am – 8:30am	Overview of chordoma and the State of the Art of Chordoma Clinical Management	
	Fran Hornicek, Massachusetts General Hospital	
8:35am-11:55am	Session I: Genetics & Genomics of Chordoma	
	Moderator: Paul Meltzer, National Cancer Institute	
8:35am – 8:55am	Characterization of genetic variants in the T gene in familial and sporadic chordoma	
	Rose Yang, National Cancer Institute	
8:55am - 9:15am	Identification of somatically acquired mutations in chordoma exomes	
	Patrick Tarpey, Wellcome Trust Sanger Institute, UK	
9:15am - 9:35am	Whole genome sequencing of chordoma	
	Stephen Yip, BC Cancer Agency, Canada	
9:35am - 9:55am	High resolution whole genome analysis of skull base chordomas implicates FHIT loss in	
	chordoma pathogenesis	
	Roberto Diaz, University of Toronto, Canada	
9:55am - 10:15am	Discussion	
10:15am-10:30am	BREAK	
10:30am-10:50am	Do immunological events play a role in chordoma?	
10:30am-10:50am	Do immunological events play a role in chordoma?  Soldano Ferrone, Massachusetts General Hospital	
10:30am-10:50am	Session I: Genetics & Genomics of Chordoma Continued	
10:30am-10:50am	Soldano Ferrone, Massachusetts General Hospital  Session I: Genetics & Genomics of Chordoma Continued  Moderator: Paul Meltzer, National Cancer Institute	
	Session I: Genetics & Genomics of Chordoma Continued Moderator: Paul Meltzer, National Cancer Institute  DNA Methylation markers in chordoma	
10:30am-10:50am 10:50am-11:10am	Soldano Ferrone, Massachusetts General Hospital  Session I: Genetics & Genomics of Chordoma Continued  Moderator: Paul Meltzer, National Cancer Institute	
10:50am-11:10am	Session I: Genetics & Genomics of Chordoma Continued Moderator: Paul Meltzer, National Cancer Institute  DNA Methylation markers in chordoma Beate Rinner, Medical University of Graz, Austria  A molecular analysis identifies chondrogenesis as the driving mechanism of chordoma	
	Session I: Genetics & Genomics of Chordoma Continued Moderator: Paul Meltzer, National Cancer Institute  DNA Methylation markers in chordoma Beate Rinner, Medical University of Graz, Austria	
10:50am-11:10am	Session I: Genetics & Genomics of Chordoma Continued Moderator: Paul Meltzer, National Cancer Institute  DNA Methylation markers in chordoma Beate Rinner, Medical University of Graz, Austria  A molecular analysis identifies chondrogenesis as the driving mechanism of chordoma Yair Benita, Massachusetts General Hospital  The effects and expression profiling of microRNAs in chordomas	
10:50am-11:10am 11:10am-11:30am	Session I: Genetics & Genomics of Chordoma Continued Moderator: Paul Meltzer, National Cancer Institute  DNA Methylation markers in chordoma Beate Rinner, Medical University of Graz, Austria  A molecular analysis identifies chondrogenesis as the driving mechanism of chordoma Yair Benita, Massachusetts General Hospital	
10:50am-11:10am 11:10am-11:30am	Session I: Genetics & Genomics of Chordoma Continued Moderator: Paul Meltzer, National Cancer Institute  DNA Methylation markers in chordoma Beate Rinner, Medical University of Graz, Austria  A molecular analysis identifies chondrogenesis as the driving mechanism of chordoma Yair Benita, Massachusetts General Hospital  The effects and expression profiling of microRNAs in chordomas	

12:00pm-12:50pm	LUNCH Location: Buffet Lunch Served on 5 <sup>th</sup> Floor Rotunda
12:50pm-2:05pm	Session II: Molecular Biology of Chordoma Moderator: Justin Cates, Vanderbilt University
12:50pm - 1:10pm	DJ-1/PARK7 regulates oxidative stress in chordoma cells  Deric Park, University of Virginia
1:10pm - 1:30pm	Stem cells in chordomas: delineating mediators of self-renewal and tumor-initiation Sagar Shah, Johns Hopkins University
1:30pm - 1:45pm	Histone Deacetylase inhibitors in chordomas: an immunohistochemical and functional analysis in MUG-chor1 Susanne Scheipl, Medical University of Graz, Austria
1:45pm – 2:05pm	Discussion
2:05pm – 2:25pm	BREAK
2:25pm - 4:15pm	Session III: Brachyury and Chordoma Moderator: Michael Kelley, Duke University
2:25pm - 2:55pm	Control of notochord gene expression by Brachyury: lessons from a sea squirt Anna DiGregorio, Cornell
2:55pm - 3:15pm	The Role of Brachyury in Tumor Progression Claudia Palena, National Cancer Institute
3:15am – 3:35pm	The role of brachyury in chordoma pathogenesis and as a therapeutic target Adrienne Flanagan, University College London, UK
3:35pm – 3:55pm	Targeting Brachyury Using A Lipid-based Nanoparticle Delivery System for shRNA Inhibits Chordoma Cell Growth In Vitro Wesley Hsu, Wake Forest University
3:55pm – 4:15pm	Discussion
4:15pm – 4:30pm	BREAK
4:30pm – 5:30pm	Session IV: Model Development & Characterization Moderator: Brian Harfe, University of Florida
4:30pm – 4:50pm	Can the embryonic notochord model chordoma?  Cheryle Seguin, University of Western Ontario, Canada
4:50pm – 5:10pm	Developing a Zebrafish Chordoma Model  Andreas Fritz, Emory University
5:10pm – 5:30pm	Development of a genetically engineered mouse model David Alcorta, Duke University
5:30pm -5:35pm	ATCC Chordoma Cell Line Collection  Matt Klusas, ATCC
5:35pm – 5:55pm	Discussion
5:55pm – 6:00pm	WRAP UP
6:00pm – 7:20pm	Reception and Poster Session Location: 5 <sup>th</sup> Floor Esplanade and Rotunda
7:30pm – 9:00pm	DINNER Location: Liberty Ballroom – 2 <sup>nd</sup> Floor

### Friday, March 22

7:30am – 4:30pm	Registration Open
7:30am – 8:00am	Continental Breakfast Location: Liberty Ballroom Foyer – 2 <sup>nd</sup> Floor
8:00am – 8:05am	Opening Location: Liberty Ballroom – 2 <sup>nd</sup> Floor
8:05am – 8:25am	Chordoma Foundation Research Strategy Josh Sommer, Chordoma Foundation
8:25am – 10:05am	Session V: Preclinical Treatment Development Moderator: Deric Park, University of Virginia
8:25am - 8:45am	Role of MicroRNA-1 (miR-1) in chordoma and its therapeutic potential Zhenfeng Duan, Massachusetts General Hospital
8:45am - 9:05am	Identification of Repurposed Drugs for Chordoma Therapy  Menghang Xia, NCATS/NIH
9:05am - 9:25am	In vivo testing in a patient derived chordoma xenograft model Gary Gallia, Johns Hopkins University
9:25am - 9:45am	Kinase inhibitor screening Adrienne Flanagan, UCL, UK David Drewry, GlaxoSmithKline Bill Zuercher, GlaxoSmithKline
9:45am – 10:05am	Discussion
10:05am-10:25am	BREAK
10:05am-10:25am 10:25am-12:00pm	Session VI: Clinical Trials Moderator: Michael Kelley, Duke University
	Session VI: Clinical Trials
10:25am-12:00pm	Session VI: Clinical Trials Moderator: Michael Kelley, Duke University  Current state of clinical trials, update on Lapatinib and Sirolimus/Imatinib trials, New trials, European Clinical Trials Network
<b>10:25am-12:00pm</b> 10:25am - 10:55am	Session VI: Clinical Trials Moderator: Michael Kelley, Duke University  Current state of clinical trials, update on Lapatinib and Sirolimus/Imatinib trials, New trials, European Clinical Trials Network  Silvia Stacchiotti, Istituto dei Tumori, Milan, Italy  First-in-human phase 1 trial of a recombinant yeast vaccine genetically modified to express Brachyury
10:25am-12:00pm 10:25am - 10:55am 10:55am - 11:15am	Session VI: Clinical Trials Moderator: Michael Kelley, Duke University  Current state of clinical trials, update on Lapatinib and Sirolimus/Imatinib trials, New trials, European Clinical Trials Network  Silvia Stacchiotti, Istituto dei Tumori, Milan, Italy  First-in-human phase 1 trial of a recombinant yeast vaccine genetically modified to express Brachyury  Chris Heery, National Cancer Institute  Phase I Study of a Novel Hypoxia Targeting Agent for the Treatment of Solid Tumors Chetan Bettegowda, Johns Hopkins
10:25am-12:00pm 10:25am - 10:55am 10:55am - 11:15am 11:15am - 11:35am	Session VI: Clinical Trials Moderator: Michael Kelley, Duke University  Current state of clinical trials, update on Lapatinib and Sirolimus/Imatinib trials, New trials, European Clinical Trials Network  Silvia Stacchiotti, Istituto dei Tumori, Milan, Italy  First-in-human phase 1 trial of a recombinant yeast vaccine genetically modified to express Brachyury  Chris Heery, National Cancer Institute  Phase I Study of a Novel Hypoxia Targeting Agent for the Treatment of Solid Tumors Chetan Bettegowda, Johns Hopkins  Saurabh Saha, BioMed Valley Discoveries  Discussion: Prioritizing Clinical Trials  Discussants: Edwin Choy, Massachusetts General Hospital  Based on what's known about chordoma, what approaches or agents make sense to test in

1:20pm – 2:05pm	Session VII: Clinical Research Strategy Moderator: Josh Sommer, Chordoma Foundation
1:20pm – 1:35pm	Collaborating with SARC: A Sarcoma Clinical Trials Consortium  Denise Reinke, Sarcoma Alliance for Research through Collaboration
1:35pm – 2:05pm	Discussion: Clinical Trial Design and Coordination What clinical trial designs make sense for chordoma? Do we know appropriate end points for chordoma clinical trials? What opportunities exist to facilitate and coordinate trials across centers?  Discussants: Peter Hohenberger, University of Heidelberg, Germany Silvia Stacchiotti, Istituto dei Tumori, Milan, Italy Tim Rodell, Globeimmune
2:10pm – 3:40pm	Session VIII: Outcomes and Natural History Research Moderator: Bradford Hirsch, Duke University
2:10pm – 2:30pm	AOSpine Tumor Knowledge Forum Biobank Chetan Bettegowda, Johns Hopkins
2:30pm – 2:50pm	Prospective chordoma patient database: a European initiative Carmen Vleggeert-Lankamp, University of Leiden, Netherlands
2:50pm – 3:10pm	Beyond the Surgical Treatment – Developing Novel Interactive Tools for Patient–reported Quality of Life Data Collection  Kathryn Hess and Joe Schwab, Massachusetts General Hospital
3:10pm – 3:40pm	Discussion: Defining Natural History  How can registries or natural history studies be designed to provide the information needed to improve patient care and inform appropriate end points for chordoma clinical trials?  Discussants: Dianne Finkelstein, Massachusetts General Hospital
3:40pm – 4:00pm	BREAK
4:00pm – 5:10pm	Session IX: Emerging Treatment Paradigms Moderator: Tom Delany, Massachusetts General Hospital
4:00pm – 4:20pm	Novel mechanisms of response for stereotactic radiosurgery. Food for thought for the management of Chordomas  Josh Yamada, Memorial Sloan Kettering
4:20pm – 4:40pm	Updates on Proton Clinical Trials for Chordomas  Tom DeLaney, Massachusetts General Hospital
4:40pm – 5:10pm	Discussion: Role of Neoadjuvant Therapy in Surgically Resectable Chordomas  Discussants: Fran Hornicek, Massachusetts General Hospital  Mrinal Gounder, Memorial Sloan Kettering
5:10pm-5:50pm	<b>Group Brainstorming:</b> Reflect on presentations and identify key areas for future investigation
5:50pm – 6:00pm	CLOSING
6:30pm - 9:30pm	DINNER with Chordoma Patient Community Location: Wyndham Boston Beacon Hill, 15 <sup>th</sup> floor, Beacon Hill Ballroom (5 Blossom Street - three blocks east of the Liberty Hotel) - Uncommon Research Awards - Live Jazz Entertainment